Nexstim logo

Participation in Nordic Life Sciences Conference in New York

23 April 2015

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces that its Chief Executive Officer, Janne Huhtala and Chief Financial Officer, Mikko Karvinen, will participate in the 2015 Nordic Life Sciences in New York on Monday 27th April 2015.  The conference, hosted by the Trout Group and Pareto Securities, will take place at the offices of Davis Polk & Wardwell in New York City.

The conference aims to bring together many of the leading small cap life sciences companies from Finland, Sweden, Denmark, and Norway via presentations and 1 to 1 meetings. For information about the conference, please visit www.troutgroup.com/page/nordic. The Company’s presentation will be made available at www.nexstim.com following the conference.

NEXSTIM PLC

Janne Huhtala, CEO

 

For further information please visit www.nexstim.com or contact:

Nexstim                                                                                                                             

Janne Huhtala, Chief Executive Officer  
+358 (0)40 8615046                                                    
janne.huhtala@nexstim.com

UB Capital Oy (Certified Adviser)                                                                                
+358 (0)9 2538 0225

Consilium Strategic Communications                                                                      
+44 (0)20 3709 5700

Mary-Jane Elliott / Ivar Milligan / Laura Thornton                           
nexstim@consilium-comms.com

 

About Nexstim Plc

Nexstim, formed in 2000 and based in Finland, is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.

Back to Press Releases

Sorry, there are no fact sheets available. Please check back soon.

Follow us

linkedin

Twitter
YouTube